Skip to content

Allergan CEO Blog Series

Go to to check out the Allergan Blog Series by David E. I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc.

View site  >

Allergan’s Corporate Social Responsibility Program

Learn more about Allergan’s Corporate Social Responsibility Program

Learn more  >

Follow Allergan, Inc. on: Follow on Twitter

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, BOTOX® Cosmetic (onabotulinumtoxinA), and the JUVÉDERM® family of dermal fillers. Please look through this Web site for more information, including Important Safety Information, about these products and our full portfolio of products.

212.63 (0.45)
Volume 3,317,100


Learn about our worldwide locations.



11.17.14Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue
11.14.14Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
11.12.14FDA Approves New Styles of Allergan's NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
More news